Drug Trial Radar · NCT07416968
Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study
Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Sep 1, 2025
Primary completion
Sep 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Mansoura UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cairo University; Ain Shams University; Alexandria University; Zagazig University; Tanta University; Menoufia University; Assiut University; Sohag University; South Valley University; Beni-Suef University; Minia University; Aswan University
- First posted
- Feb 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are studying two medicines to see which works better for women with overactive bladder (OAB). OAB causes sudden urges to urinate, frequent bathroom trips, and sometimes leakage. Women who join the study will be randomly placed into one of two groups: One group will take tadalafil (5 mg), a medicine taken once a day. The other group will take solifenacin (5 mg), a common treatment for OAB, also taken once a day. The study will last 12 weeks. Participants will keep a bladder diary, answer short questionnaires, and have simple urine flow and bladder tests at several visits. The main goal is to find out which medicine lowers OAB symptoms more, such as urgency and frequent urination. Researchers will also look at quality of life, bladder function, and side effects. Women aged 18 to 75 years with OAB symptoms for at least 3 months may be able to take part.
Conditions
- Overactive Bladder (OAB)
- Overactive Bladder Syndrome
Interventions
Tadalafil 5 mgDrug
Tadalafil 5 mg orally once daily for the duration of 12 weeks
Solifenacin 5mgDrug
solifenacin succinate 5 mg orally once daily for the duration of 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overactive Bladder Symptom Score percentage reductionTime frame: from enrollment to 12 weeks
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Faculty of medicine, minia university
Al Minyā, Egypt · Recruiting
Faculty of medicine, Alexandria University
Alexandria, Egypt · Recruiting
Faculty of medicine, Aswan university
Aswān, Egypt · Recruiting
Faculty of Medicine - Assiut University
Asyut, Egypt · Recruiting
Faculty of Medicine - Banī Suwayf University
Banī Suwayf, Egypt · Recruiting
Faculty of medicine, Ain Shams University
Cairo, Egypt · Recruiting
Cairo University, faculty of medicine
Cairo, Egypt · Recruiting
Faculty of Medicine, South Valley University
Qina, Egypt · Recruiting
Faculty of medicine, Sohag Univeristy
Sohag, Egypt · Recruiting
Faculty of medicine, Menofia Univeristy
Shibīn al Kawm, Al-Minūfiyyah, Egypt · Recruiting
Faculty of medicine, Zagazig University
Zagazig, Al-Sharqia, Egypt · Recruiting
Urology and Nephrology Center, Mansoura University
Al Mansurah, Dakahlia Governorate, Egypt · Recruiting
Faculty of medicine, Tanta University
Tanta, Gharbia Governorate, Egypt · Recruiting
faulty of medicine, Tanta Univeristy
Tanta, Gharbia Governorate, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.